Can Preimplantation Genetic Testing Be Used for Sex Selection?
Key Takeaways
Some forms of preimplantation genetic testing (PGT) can identify an embryo's chromosomal sex. Using that information to reduce the risk of a serious sex-linked condition is different from choosing a sex for personal preference: non-medical selection is ethically controversial, laws vary by country, and it is not offered by our clinic in Turkey.
Key evidence: ASRM Ethics Committee Opinion on Non-Medical Sex Selection (2022) ESHRE Good Practice Recommendations for PGT (2021) ACOG Committee Opinion on Preimplantation Genetic Testing
On this page
- How PGT Examines Embryo Genetics and Sex
- When Sex Selection Is Medically Indicated
- Non-Medical Sex Selection and Ethical Concerns
- International Legal Variations and Turkish Regulations
- Clinical Perspective: Prioritizing Embryo Health Over Sex Selection
- FAQ
- Related Reading
- Sources
How PGT Examines Embryo Genetics and Sex
Preimplantation genetic testing (PGT) examines cells sampled from an embryo created through in vitro fertilisation (IVF). Some forms of PGT analyse the sex chromosomes, so the laboratory may be able to identify an embryo’s chromosomal sex. That technical possibility is not, by itself, a medical reason to choose an embryo for transfer.
PGT encompasses three distinct clinical methodologies (ESHRE Good Practice Recommendations, 2021):
- PGT-A (testing for aneuploidy): Estimates whether the sampled cells show gains or losses of chromosomes. It is a screening test, not a guarantee that an embryo is genetically healthy or will implant.
- PGT-M (testing for monogenic conditions): Looks for a specific inherited variant identified in a family, such as one associated with cystic fibrosis, sickle cell anaemia or Huntington’s disease (see our detailed guide to PGT-M for monogenic conditions).
- PGT-SR (testing for structural rearrangements): Looks for unbalanced chromosome material when a parent carries a known structural rearrangement, such as a translocation or inversion.
Testing commonly uses a small sample of trophectoderm cells from a blastocyst. Whether chromosomal sex is reported depends on the test, the clinical indication, local law and laboratory policy. A PGT result also describes the sampled cells; it does not test every cell of the embryo.
Dr. Senai Aksoy’s Approach
When this question comes up, I first separate two very different aims: reducing the risk of a serious inherited condition and choosing a sex for personal preference. The first may justify a carefully designed PGT-M pathway after genetic counselling. The second is not a medical indication and is not offered by our clinic. In Turkey, treatment must remain within the applicable legal and regulatory framework.
When Sex Selection Is Medically Indicated
Embryo sex may be clinically relevant when a family has a documented risk of a serious sex-linked condition. The preferred approach is usually disease-specific PGT-M, designed around the family’s confirmed genetic variant, rather than selection by sex alone.
Some inherited conditions are linked to the X chromosome. Their effects and inheritance patterns vary: males with one X chromosome may be more likely to be affected in some disorders, while females may be carriers, mildly affected or sometimes significantly affected. Examples include:
- Duchenne and Becker muscular dystrophy
- Hemophilia A and B
- Fragile X syndrome
- X-linked adrenoleukodystrophy
When a familial variant is known, a genetics team can assess whether a targeted PGT-M test is feasible. In limited situations where a reliable disease-specific test cannot be developed, sex may form part of risk assessment for a serious sex-linked disorder. Even then, sex alone does not establish whether every embryo is affected or unaffected, and prenatal diagnostic testing may still be discussed after pregnancy begins (ACOG Committee Opinion on PGT).
Non-Medical Sex Selection and Ethical Concerns
Non-medical sex selection—often referred to as “family balancing” or personal preference—involves selecting an embryo solely based on whether it is male or female when no genetic disease risk exists.
Professional bodies have identified several ethical concerns about non-medical selection, although policies differ between countries and clinics (ASRM Ethics Committee Opinion, 2022):
- Reinforcing Gender Bias: Selecting an embryo for non-medical reasons risks perpetuating societal stereotypes and gender-based discrimination.
- Narrowing the embryos considered for transfer: Prioritising sex can exclude embryos that might otherwise have been considered on clinical grounds.
- Adding treatment burden: PGT involves embryo biopsy, laboratory analysis and usually embryo freezing. Undertaking these steps solely for a non-medical preference adds cost and complexity without treating a medical condition (learn more about IVF treatment risks and considerations).
International Legal Variations and Turkish Regulations
Legal frameworks governing sex selection vary considerably across different countries:
- United States: There is no federal prohibition against non-medical sex selection, leaving policies to individual private clinics and state professional guidelines.
- United Kingdom: UK law prohibits sex selection for social reasons; embryo testing may be authorised to avoid a serious inherited condition.
- Europe: Rules are country-specific. Patients should not assume that one country’s policy represents the whole European Union.
- Turkey: In accordance with the Ministry of Health Assisted Reproductive Treatment Regulations (T.C. Sağlık Bakanlığı ÜYTE Yönetmeliği), sex selection for non-medical reasons is strictly illegal.
At our clinic in Istanbul, PGT is considered only for a documented medical or genetic indication. We do not offer embryo transfer for non-medical sex selection. Patients receive case-specific counselling because the appropriate test depends on the family history, the genetic finding and the limits of the laboratory method.
Clinical Perspective: Prioritizing Embryo Health Over Sex Selection
Embryo sex is not used as a marker of embryo quality in routine clinical decision-making. Implantation and live birth depend on several interacting factors, and no PGT result can promise either outcome.
When planning treatment, the clinical team considers factors such as:
- Chromosome findings: PGT-A may estimate whether the sampled cells are euploid, mosaic or aneuploid, but it does not establish that an embryo is healthy in every genetic respect.
- Embryo morphology: The appearance and development of the inner cell mass and trophectoderm (see how to interpret embryo grades such as 4AA, 3BB and 5BC).
- Uterine and endometrial factors: The clinical team considers the uterine cavity, endometrium and transfer conditions rather than relying on a single measurement.
- Age and the wider clinical picture: Age, ovarian response, sperm factors, embryo development and previous treatment history all contribute to planning.
Restricting transfer to one sex can reduce the number of embryos available for consideration. It does not make the remaining embryos more likely to implant simply because of their sex.
FAQ
Does every PGT report disclose embryo sex?
No. While modern genetic sequencing technologies identify sex chromosomes, disclosure of embryo sex depends on national law and clinic policy. In jurisdictions where non-medical sex selection is prohibited, laboratory reports omit or mask sex chromosome information unless needed for an approved medical indication.
Is “family balancing” considered a medical indication?
No. Family balancing—the desire to have a child of a specific sex after having children of the opposite sex—is categorized as a non-medical request. It is treated separately from disease prevention by regulatory bodies and is prohibited under Turkish law.
Does choosing embryo sex improve IVF success rates?
No. Choosing an embryo because of its sex is not a method for improving IVF success. Prognosis depends on the full clinical picture, and even an embryo reported as euploid after PGT-A cannot guarantee implantation or live birth.
Can international patients request non-medical sex selection in Turkey?
No. All reproductive medical treatments conducted in Turkey are bound by Turkish healthcare law regardless of patient nationality. Non-medical sex selection is strictly prohibited for both domestic and international patients across all licensed centers in Turkey.
Related Reading
- PGT-M for Monogenic Diseases: How It Works and What It Can and Cannot Do
- Embryo Grades Like 4AA, 3BB, and 5BC: What They Actually Mean
- IVF Risks and Practical Considerations: What Patients Should Know
Sources
- American Society for Reproductive Medicine (ASRM) Ethics Committee. Use of reproductive technology for sex selection for nonmedical reasons: an Ethics Committee opinion (2022).
- European Society of Human Reproduction and Embryology (ESHRE) PGT-Special Interest Group. ESHRE PGT Consortium good practice recommendations for the detection of structural and numerical chromosomal aberrations (2021).
- American College of Obstetricians and Gynecologists (ACOG) Committee on Genetics. Preimplantation Genetic Testing: ACOG Committee Opinion No. 799.
- American Society for Reproductive Medicine (ASRM) Practice Committee. The use of preimplantation genetic testing for aneuploidy (PGT-A): a committee opinion (2024).
- Republic of Turkey Ministry of Health. Regulation on Assisted Reproductive Treatment Practices and Centers (Üremeye Yardımcı Tedavi Uygulamaları ve Merkezleri Hakkında Yönetmelik).
Add as a Preferred Source on Google
You can add draksoyivf.com as one of your preferred health information sources on Google.
The content has been created by Dr. Senai Aksoy and medically approved.